This article is more than 5 years old. Information may no longer be current.

Luqa Pharmaceuticals acquires common stock of Arista

Luqa Pharmaceuticals has acquired the outstanding common stock of the aesthetic and surgical solutions company Arista, according to a press release today.

The deal will allow Luqa to bring Aethoxyskerol, a treatment for varicose veins, to a wider patient population in China, according to the statement. The company has also suggested that the acquisition will put Luqa in a position to offer a broader range of treatments in the aesthetics field.

An executive at Luqa noted that aesthetics is a fast-growing field in health care, while an executive at Arista is hopeful that the arrangement will allow the full pipeline of Arista products to reach a larger market of potential patients. – by Rob Volansky